ACEA Biosciences
Xiaoyu Zhang has worked as a Research Scientist at ACEA Biosciences since 2011. In this role, Xiaoyu has been responsible for developing applications on the xCELLigence RTCA Cardio system and overseeing the cardiac safety screening program.
Prior to that, Xiaoyu worked at ScienCell Research Laboratories from 2008 to 2011. In this position, Xiaoyu served as a scientist and group leader of the media production department. Xiaoyu's main responsibilities included the development of Embryonic Stem Cell (ESC) feeder layer free and serum free media.
Before joining ScienCell Research Laboratories, Xiaoyu worked as a Postdoctoral Associate at the Burnham Institute for Medical Research in La Jolla, CA from 2007 to 2008.
Xiaoyu Zhang obtained a Ph.D. in Cell Molecular and Development Biology from the University of California, Riverside, where they studied from 2001 to 2007.
ACEA Biosciences
ACEA Biosciences is a biotechnology company founded in 2002 and headquartered in San Diego, California. ACEA is a pioneer in the development and commercialization of high-performance microelectronic systems for cell-based assays. ACEA has a world-class manufacturing operation centered in Hangzhou, Zhejiang Province, China.The Life TechnologyBusiness Unit developed ACEA’s proprietary real-time, label-free cell-based assay technology and launched the first product in 2004. The technology has been marketed globally under the xCELLigence brand. There are over 800 customers worldwide, and over 350 peer-reviewed publications using the xCELLigence technology.The newly launched iCELLigence instrument with wireless connectivity makes this innovative technology affordable to all users. In addition to the Life Technology Business Unit, ACEA also has a Therapeutics Business Unit which was launched in 2005.ACEA Therapeutics is focused on oncology drug discovery and development, leveraging the platform biosensor technology and proprietary small molecule library (> 1 million compounds) to bring novel therapeutics into the clinic. ACEA currently has one program in phase II clinical trials in China and numerous early clinical and preclinical leads. With its international reach, ACEA Biosciences continues to work closely with scientists throughout the world to bring innovation to the R&D and health care industries.